Exploring Analyst Estimates for Boston Scientific (BSX) Q2 Earnings, Beyond Revenue and EPS

The upcoming report from Boston Scientific (BSX) is expected to reveal quarterly earnings of $0.72 per share, indicating an increase of 16.1% compared to the year-ago period. Analysts forecast revenues of $4.89 billion, representing an increase of 18.7% year over year.The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.Prior to a company's earnings release, it is of utmost importance to factor in any revisions made to the earnings projections. These revisions serve as a critical gauge for predicting potential investor behaviors with respect to the stock. Empirical studies consistently reveal a strong link between trends in earnings estimate revisions and the short-term price performance of a stock.While it's common for investors to rely on consensus earnings and revenue estimates for assessing how the business may have performed during the quarter, exploring analysts' forecasts for key metrics can yield valuable insights.Bearing this in mind, let's now explore the average estimates of specific Boston Scientific metrics that are commonly monitored and projected by Wall Street analysts.Analysts expect 'Net Sales- MedSurg- Worldwide' to come in at $1.68 billion. The estimate indicates a change of +13.1% from the prior-year quarter.The collective assessment of analysts points to an estimated 'Net Sales- Cardiovascular- Worldwide' of $3.21 billion. The estimate points to a change of +21.7% from the year-ago quarter.The consensus among analysts is that 'Net Sales- Cardiovascular- Cardiology- Worldwide' will reach $2.52 billion. The estimate points to a change of +23.3% from the year-ago quarter.According to the collective judgment of analysts, 'Net Sales- Cardiovascular- Peripheral Interventions- Worldwide' should come in at $689.56 million. The estimate indicates a year-over-year change of +16.9%.The combined assessment of analysts suggests that 'Geographic Revenue- U.S.' will likely reach $3.06 billion. The estimate indicates a year-over-year change of +24.1%.Analysts' assessment points toward 'Net Sales- Cardiovascular- Peripheral Interventions- International' reaching $309.92 million. The estimate indicates a year-over-year change of +10.3%.Analysts predict that the 'Net Sales- MedSurg- Neuromodulation- United States' will reach $220.82 million. The estimate points to a change of +3.2% from the year-ago quarter.Based on the collective assessment of analysts, 'Net Sales- MedSurg- Neuromodulation- International' should arrive at $70.31 million. The estimate indicates a year-over-year change of +3.4%.The average prediction of analysts places 'Net Sales- MedSurg- Endoscopy- United States' at $445.09 million. The estimate suggests a change of +7.3% year over year.Analysts forecast 'Net Sales- MedSurg- Endoscopy- International' to reach $273.79 million. The estimate suggests a change of +4.9% year over year.It is projected by analysts that the 'Net Sales- MedSurg- Urology- United States' will reach $492.40 million. The estimate indicates a year-over-year change of +35.7%.The consensus estimate for 'Net Sales- MedSurg- Urology- International' stands at $177.83 million. The estimate suggests a change of +9.8% year over year. View all Key Company Metrics for Boston Scientific here>>> Over the past month, shares of Boston Scientific have returned +3.2% versus the Zacks S&P 500 composite's +5.4% change. Currently, BSX carries a Zacks Rank #2 (Buy), suggesting that it may outperform. the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .5 Stocks Set to DoubleEach was handpicked by a Zacks expert as the favorite stock to gain +100% or more in the months ahead. They includeStock #1: A Disruptive Force with Notable Growth and ResilienceStock #2: Bullish Signs Signaling to Buy the DipStock #3: One of the Most Compelling Investments in the MarketStock #4: Leader In a Red-Hot Industry Poised for GrowthStock #5: Modern Omni-Channel Platform Coiled to SpringMost of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor. While not all picks can be winners, previous recommendations have soared +171%, +209% and +232%.Download Atomic Opportunity: Nuclear Energy's Comeback free today.Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Boston Scientific Corporation (BSX): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks